Anebulo shares rise 10.04% premarket after announcing cash tender offer for 300,000 shares at $3.50, a 61% premium.

Anebulo Pharmaceuticals (ANEB) rose 10.04% in premarket trading following its announcement of a voluntary cash tender offer to repurchase up to 300,000 shares at $3.50 per share, a 61% premium over its current price of $2.17. The company abandoned its previously announced reverse stock split plan due to rising costs from multiple account purchases, which diluted potential benefits for shareholders. The tender offer aims to reduce shareholder count below 300 to facilitate a planned capital transaction, while its strong liquidity (current ratio of 10.93) supports the move. The premium pricing and shift toward a more shareholder-friendly structure likely drove the premarket rally.